Read

Relyvrio and the ALS Treatment Landscape

Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s Disease, is a rare, progressive, neurodegenerative disorder that affects nerve cells in the spinal cord and the brain. These motor neurons govern voluntary movement and muscle control. ALS causes motor neurons to degenerate and eventually die, resulting in muscle weakness, disability and eventually death. The …

Relyvrio and the ALS Treatment Landscape Read More »

Enhertu: The New Oncology ‘Smart Bomb’

An article on Health.com recently quoted me about an exciting new FDA-approved drug shown to extend metastatic breast cancer patients’ lives significantly. Enhertu is a combination of two known therapies, trastuzumab and deruxtecan work in tandem to target the lower levels of HER2 proteins present.   As I described in the article, these two therapies work …

Enhertu: The New Oncology ‘Smart Bomb’ Read More »

Mounjaro: Competing To Be the Best

Jason Peterson and RemedyOne EVP of clinical services Robert Louie have also written about Mounjaro for Pharmaphorum.  Man o’ War, Seabiscuit, Secretariat, Seattle Slew, Trulicity, Ozempic, Rybelsus, and Mounjaro. Racehorses and treatments for diabetes—all of which have a history of competing to be the best.    Just over 11% of the U.S. population currently has …

Mounjaro: Competing To Be the Best Read More »

Drug Treatment of Presbyopia: Medical Necessity or Convenience?

Some say things get better with age. Cheese, wine, and whiskey are a few examples that come to mind. Unfortunately, your vision is not one of them. As we enter our forties, most if not all of us will experience the natural loss of near vision, also known as presbyopia. Coined from the Greek terms …

Drug Treatment of Presbyopia: Medical Necessity or Convenience? Read More »

Six Months After Authorization, What Do We Know About Paxlovid?

See this article by RemedyOne EVP of clinical services Robert Louie as it originally appeared in Pharmaphorum.  It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with …

Six Months After Authorization, What Do We Know About Paxlovid? Read More »

How the Pharmaceutical Industry Can Turn the Tide on Mental Health

May is Mental Health Awareness Month. RemedyOne president Ralph Pisano wrote this article for Fierce Healthcare about how the pharmaceutical industry can do more to address the mental health crisis. The stigma of mental health disorders is slowly disappearing, and that’s a very good thing. You see evidence of this everywhere: on TV and social …

How the Pharmaceutical Industry Can Turn the Tide on Mental Health Read More »

New Developments in Macular Degeneration/Diabetic Eye Disease

Visual impairment can be a major health issue for older adults, ranging from a minor inconvenience to vision loss significantly impacting quality of life.  Age-related macular degeneration (AMD) is a neurodegenerative disease of the retina and would fall into the latter category. It’s the leading cause of irreversible vision loss among the elderly. In 2016, …

New Developments in Macular Degeneration/Diabetic Eye Disease Read More »

Drug Innovation Continues Despite a World-Wide Pandemic

While much of the world was on pause during the COVID-19 pandemic, there are definite signs that even a pandemic cannot hold back drug innovation. Despite the variety of challenges posed by the dreaded contagion, the FDA continued to churn out drug approvals in 2021 and innovate health advancements for the American public. Historically, December …

Drug Innovation Continues Despite a World-Wide Pandemic Read More »